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9.3) pg/mL compared to uneventful pregnancies 17.3 (9.8–
26.0) pg/mL ( p = 0.0011).  Conclusion: The discriminatory ac-
curacy of PlGF increases from 10 to 14 weeks of gestation, 
and serial PlGF measurements might be of particular interest 
in PE screening.   © 2017 S. Karger AG, Basel 
 Introduction 
 Preeclampsia (PE) affects 2–3% of all pregnancies and 
is a major cause of maternal and fetal morbidity and mor-
tality worldwide  [1–3] . The only validated treatment to-
day remains delivery, but prevention with low-dose aspi-
rin (LDA) initiated before 16 weeks of gestation in wom-
en at risk has been shown to be effective  [4] . Therefore it 
is important to identify women at increased risk to de-
velop PE early in pregnancy to allow timely intervention 
with LDA. The National Institute of Clinical Excellence 
(NICE) and others propose screening by anamnestic and 
clinical risk factors alone  [5] ; however, about half of all 
women who develop PE have no classical risk factor  [6] . 
To overcome this limitation, various biochemical, bio-
physical, and ultrasound markers have been identified as 
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 Abstract 
 Objective: The aims of this study were to test whether the 
performance of first-trimester placental growth factor (PlGF) 
in screening for preterm preeclampsia (PE) is gestational age 
dependent and to assess the value of serial first-trimester 
PlGF measurements in discriminating women at risk for PE. 
 Methods: PlGF was measured in women with singleton 
pregnancies at their first antenatal visit at 8+0 to 10+6 and 
additionally at 11+0 to 14+0 weeks of gestation. The differ-
ence in absolute values of serial PlGF measurements was ex-
pressed as Δ-PlGF. Values were compared between preg-
nancies with normal outcome and those complicated by PE. 
 Results: A total of 814 pregnancies were included, 18 (2.19%) 
developed PE that required delivery before 37 weeks of ges-
tation. PlGF increases significantly from 8 to 14 weeks of ges-
tation (ρ = 0.63;  p < 0.0001) in normal pregnancies, but not 
so in preterm PE (ρ = 0.034;  p = 0.893). PlGF discriminates 
between PE and uneventful pregnancies only after 10 weeks 
of gestation. Δ-PlGF was significantly lower in PE 5.3 (–1.1 to 
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possible candidates for more objective screening purpos-
es  [7–10] . Algorithms to calculate the risk for early or late 
PE have been developed, combining some of these mark-
ers with the background risk defined by maternal history. 
The performance of such a screening is best for early PE 
requiring delivery before 34 weeks of gestation, but the 
detection of later PE is also possible  [6, 11–13] . Placental 
growth factor (PlGF) is one of the most important first-
trimester biochemical markers for PE. Compared to un-
eventful pregnancies, significantly lower maternal serum 
levels of PlGF have been reported in pregnancies compli-
cated by PE, in particular early-onset forms  [14] .
 In screening for aneuploidies, it has been shown that 
timing the assessment of the biochemical markers β-
human chorionic gonadotropin and pregnancy-associat-
ed plasma protein A at 9–10 weeks of gestation substan-
tially increases the test sensitivity and specificity  [15] . 
Therefore, it was proposed to draw blood at this gesta-
tional age and combine it with nuchal translucency mea-
surements performed at 11–14 weeks of gestation  [15] .
 The aim of this study was to investigate the behavior 
of PlGF from 8 to 14 weeks of gestation in uneventful 
pregnancies and in those complicated by preterm PE and 
to explore whether the PE screening performance of PlGF 
is gestational age dependent. Additionally, we wanted to 
test the value of serial first-trimester PlGF measurements 
in discriminating women at risk for PE.
 Material and Methods 
 This was a prospective cross-sectional and partly longitudinal 
study of consecutive pregnant women attending for their first rou-
tine antenatal visit between 8 and 14 weeks of gestation and who 
underwent PE screening between January 2014 and December 2015 
at the outpatient clinic of our Department. We included consecutive 
patients with singleton pregnancy, who agreed to participate in the 
study and of whom outcome data were available. Exclusion criteria 
were: multiple pregnancies, pregnancies complicated by structural 
or chromosomal anomalies, and pregnancies resulting in fetal loss 
before 24+0 weeks of gestation. For the cross-sectional analysis of 
our results, pregnancies resulting in term PE were excluded. 
 PlGF was measured at the first antenatal visit between 8+0 and 
10+6 weeks of gestation if the patient presented before 11 weeks 
and again at the time of first-trimester screening for PE at 11+0 to 
14+0 weeks of gestation using the algorithm provided by the Fetal 
Medicine Foundation (FMF). Due to the low prevalence of PE in 
our cohort, we retrospectively analyzed also stored first-trimester 
serum samples of women who were referred to our service because 
of PE. PlGF was analyzed on Kryptor Compact Plus (Brahms 
GmbH) from mostly fresh or, in the case of retrospective analyses, 
frozen blood samples. The detection range for PlGF using this in-
strument is 0.03–7,000 pg/mL. For the cross-sectional analysis of 
our results, only the first PlGF measurement was used for statistical 
purposes. In patients with 2 samples, Δ-PlGF was calculated as the 
absolute values of the difference of both measurements. As the time 
interval between the 2 PlGF assessments is not standardized, and 
additionally, PlGF changes with gestational age in normal pregnan-
cies, we decided for comparative purposes to calculate the Δ-PlGF 
per time interval in days between the 2 measurements (Δ-PlGF/d). 
For the analysis of Δ-PlGF, additionally a subgroup analysis was 
performed, matching each patient who later developed PE with 3 
patients with uneventful pregnancies. The matching criteria were 
ethnicity, cigarette smoking, preexisting diabetes, method of con-
ception, maternal age and weight. All these factors have been shown 
to affect the serum concentration of PlGF  [16] . The outcome of the 
pregnancy was obtained from the clinical data system. 
 PE was defined according to the criteria established by the In-
ternational Society for the Study of Hypertension in Pregnancy: 
systolic blood pressure of 140 mm Hg or more and/or diastolic 
blood pressure of 90 mm Hg or more preexisting or developing af-
ter 20 weeks of gestation in a previously normotensive woman oc-
curring together with proteinuria defined as 300 mg or more in
24 h and/or other signs of maternal endothelial dysfunction and/or 
uteroplacental dysfunction with intrauterine growth restriction 
 [17] . Small for gestational age was defined as birthweight below the 
5th percentile for gestational age as provided by the software of the 
FMF for screening for PE  [18] . The study was approved by the Eth-
ics Committee of the University of Bern. Written informed consent 
was obtained from each woman agreeing to participate in the study.
 Statistical analysis was performed with GraphPad version 5.0 
for Windows (GraphPad Software, San Diego, CA, USA). Spear-
man rank correlation and linear regression were used to analyze 
the correlation between gestational age and absolute PlGF values 
in normal pregnancies and those complicated by PE. Continuous 
variables were analyzed using the Student  t test or Mann-Whitney 
U test while proportions were evaluated utilizing the Fisher exact 
test. Statistical significance was considered achieved when  p was 
less than 0.05.
 Results 
 During the study period, 814 pregnancies were includ-
ed; 342 women had a first PlGF measurement between 
8+0 and 10+6 weeks of gestation, 302 of them also had a 
second measurement between 11+0 and 14+0 weeks of 
gestation. The remaining 473 women had a PlGF mea-
surement between 11+0 and 14+0 weeks of gestation.
 A total of 789 uneventful pregnancies were compared 
with 18 (2.19%) pregnancies that developed PE, which 
required delivery before 37 weeks of gestation. Patient 
characteristics and pregnancy outcomes are shown in  Ta-
ble 1 . As expected, women who developed PE were more 
often nulliparous, had chronic hypertension, and delivery 
was at an earlier gestational age. Moreover, a higher inci-
dence of small-for-gestational-age children was noted.
 PlGF increases significantly from 8 to 14 weeks of ges-
tation (ρ = 0.63;  p < 0.0001) in normal pregnancies, while 
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in those complicated by preterm PE no such gestational 
age-dependent behavior can be demonstrated (ρ = 0.034; 
 p = 0.893) ( Fig. 1 ). The median (IQR) PlGF in preterm PE 
is 20.95 (17.08–24.43) pg/mL. Compared to the PlGF me-
dians of normal pregnancies calculated for each gesta-
tional week, a significant and steadily increasing differ-
ence can be demonstrated from 10+0 weeks onwards, 
while before 10 weeks of gestation, PlGF does not dis-
criminate between the 2 groups ( Fig. 2 ).
 Δ-PlGF values were available from 295 normal and 7 
PE pregnancies, 4 requiring delivery before and 3 at term. 
Median (IQR) Δ-PlGF in the PE group is 5.3 (–1.1 to 9.3) 
pg/mL compared to 17.3 (9.8–26.0) pg/mL in pregnan-
cies without PE ( p = 0.0011). Δ-PlGF also shows a sig-
nificant increase with increasing time interval between 
the 2 measurements in normal pregnancies (ρ = 0.346,
 p < 0.0001), but not in PE ( p = 0.302). Mean gestational 
age at which blood was drawn was not statistically differ-
ent between the groups for both measurements (9.8 ± 0.6 
vs. 10.0 ± 1.1 weeks [ p = 0.34] at the first and 12.7 ± 0.6 
vs. 12.2 ± 0.6 weeks [ p = 0.171] at the second measure-
ment). The 7 PE pregnancies were matched with 21 nor-
mal pregnancies in the above-described manner. In this 
subgroup analysis, Δ-PlGF as well as Δ-PlGF/d were sig-
nificantly higher in normal pregnancies compared to PE 
pregnancies (14.9 [8.8 to 24.4] vs. 5.3 [–1.1 to 9.3] pg/mL 
[ p = 0.0027] and 0.69 [0.49 to 1.11] vs. 0.31 [–0.08 to 0.62) 
pg/mL/d [ p = 0.013], respectively).
 Table 1.  Patient characteristics and pregnancy outcome in the study population
PE (n = 18) No PE (n = 789) p
Maternal age, years 29.6 ± 4.5 30.8 ± 5.4 ns
BMI at 12 weeks 26.4 ± 5.4 24.0 ± 4.8 0.032
Cigarette smoker 0 71 (9.1) ns
Preexisting diabetes mellitus 0 6 (0.8) ns
Chronic hypertension 3 (16.7) 11 (1.4) 0.003
SLE or APS 0 7 (0.9) ns
Parity
Nulliparous 14 (77.8) 373 (47.0) 0.015
Parous, previous PE 3 (16.7) 22 (2.8%) 0.016
Parous, previous SGA 0 (0) 23 (2.9) ns
Parous, previous PE and SGA 1 (5.6) 5 (0.6) ns
Parous, no PE or SGA 0 (0) 366 (46.7) <0.001
Conception
Spontaneous 18 (100%) 753 (95.5) ns
ART 0 36 (4.3) ns
Ethnicity
White 14 (77.8) 575 (72.9) ns
Black 4 (22.2) 118 (14.9) ns
South Asian 0 41 (5.1) ns
East Asian 0 36 (4.6) ns
Mixed 0 19 (2.4) ns
Delivery
Vaginal 0 409 (51.3) <0.001
Operative vaginal delivery 0 96 (12) ns
Cesarean section 18 (100%) 284 (35.6) <0.001
Gestational age at delivery 33.0 (25.4 – 35.0) 39.6 (25.9 – 42.1) <0.001
Delivery before 37 + 0 weeks 18 (100%) 44 (5.6%) <0.001
Birth weight, g 1,470 (530 – 2,745) 3,340 (730 – 4,670) <0.001
Birth weight percentile 22.1 ± 21.8 44.5 ± 26.3 <0.001
<10 percentile 7 (38.9) 78 (9.9) 0.001
<5 percentile 3 (16.7) 33 (4.2) 0.042
 Data are presented as n (%), mean ± SD, or median (range). ART, assisted reproductive technology; SLE, 
systemic lupus erythematous; APS, antiphospholipid antibody syndrome; ns, not significant. Comparisons 
between the normal and PE groups: Fisher exact test for categorical variables and Student t test for continuous 
variables.
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they were also able to show a significant increase in PlGF, 
mainly from 10 weeks onwards. Pandya et al.  [16] exam-
ined the performance of PlGF in first-trimester screening 
for Down syndrome and described a similar behavior of 
PlGF measured before 11 weeks and PlGF assessed be-
tween 11 and 14 weeks of gestation. However, in their 
study the number of patients with an assessment of PlGF 
before 11 weeks of gestation has not been provided, but 
mentioned to be low. Also, even if PlGF measured before 
11 weeks is as good in distinguishing trisomy 21 from eu-
ploid pregnancies as PlGF assessed at 11 and 14 weeks, 
one cannot conclude that the same is true in screening for 
PE. Crovetto et al.  [22, 23] performed the only other 2 
studies that exist to our knowledge investigating early 
 Discussion 
 Our results show that PlGF increases steadily from 
early to late first trimester in normal pregnancies, while 
in pregnancies complicated by preterm PE this gestation-
al age-dependent first-trimester behavior of PlGF is not 
evident. Therefore, the capability of PlGF to discriminate 
between pregnant women at low and those at increased 
risk for PE is better when it is assessed late in the first tri-
mester. Of note, before the 11th week of gestation, PlGF 
seems to be of no value for PE screening purposes. How-
ever, the combination of an early PlGF assessment (<11 
weeks of gestation), with one performed between 11 and 
14 weeks and expressed as Δ-PlGF, adds further discrim-
inatory power to this angiogenic marker. Indeed, a low 
Δ-PlGF as well as a reduced increase in PlGF per day in-
creases significantly the risk of developing PE later during 
pregnancy. 
 Most studies investigating the role of PlGF as screen-
ing parameter were conducted between 11 and 14 weeks 
 [6, 14, 19] . Zhong et al.  [20] summarized these results in 
a recently published meta-analysis and concluded that 
PlGF is a good predictive marker for PE, especially PE oc-
curring before 34 weeks of gestation. Less information 
exists on the behavior of PlGF before 11 weeks of gesta-
tion. Wortelboer et al.  [21] performed longitudinal mea-
surements of several angiogenic and biochemical mark-
ers in 68 women with uneventful pregnancies between 6 
and 13 weeks of gestation and, similar to our findings, 
0
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 Fig. 1. The course of PlGF during the first trimester in patients who 
developed preterm PE compared to pregnancies without PE using 
linear regression analysis. 
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p
8+0 to 8+6 19.2 (16.7 – 25.5) 0.855
9+0 to 9+6 21.7 (16.3 – 25.7) 0.577
10+0 to 10+6 27.8 (22.0 – 36.1) 0.0014
11+0 to 11+6 32.1 (26.2 – 42.3) <0.0001
12+0 to 12+6 40.6 (31.5 – 54.2) <0.0001
13+0 to 14+0 47.1 (37.0 – 62.0) <0.0001
 Fig. 2. Median PlGF according to the gestational age of normal 
pregnancies compared to pregnancies complicated by preterm PE 
(median 20.95 pg/mL) demonstrating a significant difference from 
10+0 to 10+6 weeks onward. The included table shows the com-
parison for each gestational week of median (IQR) PlGF in un-
eventful pregnancies compared to the median PlGF of pregnancies 
complicated by preterm PE. 
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PlGF for PE screening. They analyzed different angiogen-
ic markers from 8 to 11 weeks and demonstrated an im-
provement of the screening performance when PlGF was 
included in a screening algorithm. Of note, in their larger 
study, the median (range) first-trimester PlGF of preg-
nancies complicated by early PE (<34 weeks of gestation) 
was 21.9 pg/mL (14.8–31.6), which is very similar to the 
PlGF concentration we found in our cases with preterm 
PE. The median (range) gestational age in their study was 
10.1 (9.1–10.6) weeks of gestation; just around this gesta-
tional age, we started to demonstrate a difference in PlGF 
in normal pregnancies compared to PE pregnancies also 
in our smaller cohort. However, our results demonstrate 
that the distinction of PE from normal pregnancies by 
PlGF is better at a later gestational age.
 Others have studied serial measurements of PlGF be-
fore, mostly between the first and the second trimester of 
pregnancy, but also longitudinally throughout gestation 
in normal and high-risk pregnancies  [24–28] . However, 
our study is so far the only one investigating serial PlGF 
assessments during the first trimester. Cumulatively, all 
these studies demonstrate significantly lower levels of 
PlGF throughout gestation in women who later develop 
PE and conclude that repeat measurements are likely to 
be better predictors of PE than a measurement at a single 
time point. The same conclusion could be drawn for oth-
er angiogenic and anti-angiogenic markers like soluble 
fms-like tyrosine kinase 1, soluble endoglin, or soluble 
VEGF receptor-1  [24, 25, 28] . Our results are therefore in 
line with previously described findings, but show, that se-
rial measurements are already of use in the first trimester. 
So, while a single PlGF measurement early in the first tri-
mester does not help to distinguish between PE and nor-
mal pregnancies, there is value in assessing PlGF between 
8 and 11 weeks of gestation when combined with a second 
measurement towards the end of the first trimester. The 
optimal gestational ages for assessing serial measure-
ments and the ideal time interval between the 2 measure-
ments, however, must still be defined in larger studies. If 
serial assessments of PlGF prove to be better predictors 
for PE than a single measurement, first-trimester mea-
surements are of particular interest, as LDA to prevent PE 
should be started early in pregnancy  [4] . 
 Screening for trisomies is shifting from combined 
screening to cell-free DNA screening, which makes opti-
mal timing of measuring biomarkers for Down syndrome 
less important  [15, 29, 30] . On the other hand, the FMF 
is carrying out an international multicenter trial (ASPRE 
project) to examine the use of LDA in preventing PE in 
women who screen positive in a combined first-trimester 
PE screening test  [31] . The results are awaited within a 
year’s time. If this randomized study confirms the prom-
ising results of Park et al.  [32] , who showed a very sig-
nificant reduction in preterm PE after administrating 
LDA to pregnant women who screened positive in this 
test, the uptake of such PE screening will likely be impor-
tant. According to our results, the assessment of a single 
PlGF value in combined PE screening should not be per-
formed before the time of ultrasound and biophysical 
screening, and the whole test should best be performed 
only after 12 weeks of gestation. The same is true for ear-
ly anomaly scanning, which also performs better late in 
the first trimester  [15] .
 The strength of this study is that we have used a well-
defined population at low risk and that all PlGF measure-
ments were performed in the same laboratory using 
Kryptor Compact Plus (Brahms GmbH), which is sensi-
tive in detecting PlGF also at low values. Indeed, we were 
able to obtain a result from all samples. Compared to oth-
er studies, this allowed us to analyze the course of PlGF at 
early gestational age.
 The main limitation of our study is the low prevalence 
of cases in which Δ-PlGF could be compared between PE 
and uneventful pregnancies. 
 Conclusion 
 First-trimester screening is shifting from merely as-
sessing the fetal risk for aneuploidies to a more complete 
exam including screening for placenta-associated mater-
nal pregnancy complications. In screening for PE, PlGF 
has shown good discriminatory properties in large trials. 
Our results show that this distinction can be demonstrat-
ed from the 11th week of gestation onwards and is most 
significant at the end of the first trimester. Serial measure-
ments of PlGF in the first trimester allowing to calculate 
Δ-PlGF seem to be of particular interest; however, larger 
studies are needed to test if integrating Δ-PlGF in a 
screening algorithm improves PE screening.
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